

Plan Design Optimization Saves Extra 19% for Medical Technology and Service Provider

The Situation

A manufacturer with over 4,700 members in the Western United States was unhappy with their pharmacy arrangement and needed expert advice to help curb spend. Their plan was not protecting them from rising costs and high-dollar claims, and they did not have the support they needed from their PBM. The company needed a new pharmacy benefits partner.



4,700
Members

The Solution

The manufacturer partnered with RxBenefits to conduct an in-depth analysis of their contract and plan design. Our expert clinical pharmacists provided a free Pharmacy Performance Analysis and identified specific risk areas to minimize costs. They then suggested a tailored clinical and plan design strategy to maximize savings, which included:

Narrowing the Formulary

Offers better pricing and additional oversight on covered medications to maximize the use of plan dollars with limited member disruption.

Low Clinical Value Formulary Exclusions

Prevents unnecessary drug spend by removing non-essential, high-cost, low clinical value medications from the formulary.

Our clinical team continually monitored drugs in the market and updated the low clinical value drug list throughout the year, which produced additional value.

High Dollar Claim Review

Provides umbrella protection against unnecessary spending on high-cost medications by providing an independent pharmacist review of claims greater than \$1,000.

Our clinical team provided additional oversight through prior authorization reviews for certain high-cost prescription drug claims, giving the organization insight into the specific drugs contributing to its monthly plan cost and limiting its exposure.



The Impact

The client achieved **\$719k in savings** in plan cost – **19% more than projected** – over a two-year period by implementing plan design changes and clinical optimization solutions recommended by RxBenefits. The company was able to ensure its pharmacy dollars paid for the most clinically appropriate and cost-effective therapies, which created more value for its employees – all with minimal disruption.

Redirected High Cost Prescriptions Like:

\$719K
Additional Savings
Over Two Years

19%
Extra Savings
Over Projected

Enstilar
\$1,021
for 30 days

Instead,
patient
used

Calcipotriene
\$72.68
for 30 days

Xifaxan
\$1,622
for 14 days

Instead,
patient
used

**OTC
Antidiarrheal**

Uceris
\$1,754
for 30 days

Instead,
patient
used

Mesalamine
\$206.88
for 30 days

